Core Viewpoint - Kaishikadi has successfully completed nearly 1 billion yuan in financing over the past 10 months, with the latest round raising approximately 500 million yuan, led by Zhongping Capital and supported by several notable investment institutions [2][3]. Company Overview - Established in 2017, Kaishikadi is a biotechnology company focused on diseases related to bile acid metabolism disorders. The company develops innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs), initially focusing on primary biliary cholangitis (PBC) and expanding into metabolic diseases such as metabolic-associated fatty liver disease (MASH), obesity, and diabetes [3]. Product Development - The core product CS0159 has received breakthrough therapy designation and orphan drug status from the FDA, achieving significant progress. The oral tablet has successfully completed Phase II trials for MASH in the U.S., and the Phase II core study for PBC in China has concluded with promising therapeutic potential, now advancing to Phase III trials [3]. - The research team is exploring combination therapy with CS0159 and GLP-1 receptor agonists, aiming to enhance weight management and improve liver fat degeneration and inflammation, providing new treatment strategies for metabolic diseases [3]. Financing Purpose - The recent financing will primarily focus on two key areas: accelerating the global multi-center Phase III clinical trials for MASH, PBC, and obesity, and expanding the pipeline of potential best-in-class/first-in-class therapies in the metabolic disease field [4]. - The founder of Kaishikadi expressed gratitude to both new and existing shareholders for their support, emphasizing the commitment to long-term innovation and addressing unmet medical needs in metabolic diseases [4]. Investor Insights - The managing director of Gaorong Capital highlighted the significant unmet needs in the metabolic disease sector and expressed confidence in Kaishikadi's potential to become a global leader in this field, driven by the team's dedication and resilience in advancing multiple candidate pipelines to critical clinical research stages [5].

雷递网 乐天 2月10日 凯思凯迪宣布近期完成近5亿元新一轮融资，本轮融资由中平资本领投，国寿资本、清松资本、青岛国信等多家投资机构联合参投，前轮次领投方国投先 导、老股东高榕创投和康君资本继续追加投资。 e * * x and and artistic and the seen Best-in-class/First-in-class疗法。 在研核心管线获得突破性进展积极推进临床试验 截至目前，凯思凯迪在研核心产品CS0159获得了FDA突破性疗法认定与孤儿药资格且取得了多项突破性进 展，口服片剂在美国已顺利完成MASH适应症的II期试验； 在国内，针对PBC适应症的II期核心研究已结束，目前正紧锣密鼓地推进III期试验。与此同时，研究团队积极探索CS0159联合用药方案，开展了CS0159与 GLP-1受体激动剂的联合用药研究，有望从不同角度对体重进行管理，达到增强减轻体重的效果，同时在改善肝脏脂肪变性、炎症等方面发挥协同作用，为 代谢疾病的治疗提供了新的思路。 凯思凯迪创始人徐华强博士表示："期待在新老股东的共同支持下，凯思凯迪团队能够进一步加速CS0159的临床研发进程与商业化布局，充分运用公司在'基 ...